Earnings Scheduled For September 21, 2022
Companies Reporting Before The Bell
• General Mills (NYSE:GIS) is projected to report quarterly earnings at $1.00 per share on revenue of $4.72 billion.
Tongcheng Preparing to Stand on Its Own Without Trip.com and Tencent?
Key Takeaways:
A new stock exchange filing shows leading online travel agent Trip.com may have begun to sell down its longtime stake in Tongcheng, the industry’s second-largest player
China’s online travel industry is riddled with anticompetitive cross-holdings, including Trip.com’s stakes in Tongcheng and Qunar
Strong Club Med Results Fail to Lift Fosun Tourism Back to Profits
Key Takeaways
• Fosun Tourism expects to post a loss of between 150 million yuan and 250 million yuan for the first six months of this year
Citigroup Maintains Buy on Trip.com Group, Raises Price Target to $32
Citigroup analyst Brian Gong maintains Trip.com Group (NASDAQ:TCOM) with a Buy and raises the price target from $29 to $32.
InflaRx Climbs More Than 40%, Here’s 58 Biggest Movers From Yesterday
Gainers
Agile Therapeutics, Inc. (NASDAQ: AGRX) shares climbed 89.8% to close at $2.41 on Tuesday. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade.
12 Consumer Discretionary Stocks Moving In Tuesday’s Intraday Session
Gainers
Tuniu (NASDAQ:TOUR) shares rose 46.3% to $0.76 during Tuesday's regular session. As of 13:30 EST, Tuniu's stock is trading at a volume of 69.8 million, which is 39785.4% of its average full-day volume over the last 100 days. The company's market cap stands at $93.4 million.
China Loosens COVID Rules, Sending Travel, Leisure Stocks Higher: What Investors Need To Know
Chinese travel and entertainment stocks are on the rise on Tuesday on reports of loosening COVID-19 restrictions in China.
Why Is Ceragon Networks Surging By 19%? 41 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Agile Therapeutics, Inc. (NASDAQ: AGRX) jumped 88.9% to $2.3986. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade.
Benchmark Maintains Buy on Trip.com Group, Lowers Price Target to $35
Benchmark analyst Fawne Jiang maintains Trip.com Group (NASDAQ:TCOM) with a Buy and lowers the price target from $40 to $35.